The broader gene analysis was driven by the possibility of misclassified primary tumours and increasing evidence that genes associated with other cancers (e.g., BRCA1, BRCA2, CHEK2) may also influence CRC risk through shared pathways. Here, CHEK2 is linked to neoplasm.